Journey Medical Corporation cash flow to debt ratio of -48.99% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Journey Medical Corporation's free cash flow has decreased 36.31% from $-9.13M last year to $-12.44M, signaling decreasing performance

Journey Medical Corporation's debt to equity ratio is 0.83, which means that the company's assets are unhealthy financed, signaling financial risk.

Journey Medical Corporation's debt has decreased relative to shareholder equity from 1.28 last year to 0.83 today, signaling strengthened financials

Journey Medical Corporation has negative EBITDA, making leverage ratio unreliable

Journey Medical Corporation's interest coverage ratio is -1.71, which means that the company struggles to meet interest obligations, signaling financial risk.

Journey Medical Corporation's profit margin has increased (-43.29%) in the last year from -26.14% to -14.82%, signaling increasing performance

Journey Medical Corporation's short-term assets of $66.87M exceed its short-term liabilities of $37.44M

Journey Medical Corporation's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Journey Medical Corporation's return on equity of -35.57%, is lower than 15.00%, indicating bad performance

Journey Medical Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Journey Medical Corporation has insufficient public price history to evaluate earnings stability.

Journey Medical Corporation has negative free cash flow, indicating the company is burning cash rather than generating it

Journey Medical Corporation has negative free cash flow, indicating cash burn

Journey Medical Corporation's yearly earnings has increased -22.09% since last year from $-14.67M to $-11.43M, signaling increasing performance

Journey Medical Corporation's yearly revenue has increased 10.20% since last year from $56.13M to $61.86M, signaling increasing performance

ROIC -11.26% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Journey Medical Corporation's 3-year revenue CAGR of -5.66% is negative, indicating declining revenue over the past 3 years

Journey Medical Corporation had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Journey Medical Corporation has insufficient public price history to evaluate ROE consistency.

Journey Medical Corporation has insufficient data to evaluate this check.

Journey Medical Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Journey Medical Corporation is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Journey Medical Corporation has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Journey Medical Corporation has insufficient data to evaluate this check.

Journey Medical Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Journey Medical Corporation has a price-to-book ratio of 5.70x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Journey Medical Corporation has a price-to-sales ratio of 2.72x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue